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An extensive analysis of the reliability of positron emission tomography (PET) after induction treatment in patients with Hodgkin’s
disease (HD) or aggressive non-Hodgkin’s lymphoma (NHL). In all, 75 untreated patients with HD (n¼41) or aggressive NHL
(n¼34) were studied with both PET and CT scans following standard chemotherapy induction therapy (ABVD or MACOP-B) with/
without radiotherapy. Histopathological analysis was performed when considered necessary. After treatment, four out of five (80%)
patients who were PET
þ/CT
  relapsed, as compared with zero out of 29 patients in the PET
 /CT
  subset. Among the 41 CT
þ
patients, 10 out of 11 (91%) who were PET
þ relapsed, as compared with 0 out of 30 who were PET
 . The actuarial relapse-free
survival (RFS) rates were 9 and 100% in the PET
þ and PET
  subsets, respectively (P¼0.00001). All five patients who were PET
þ/
CT
  underwent a lymph node biopsy: in four (80%) cases, persistent lymphoma and was confirmed at histopathological examination.
Two HD patients who were PET
 /CT
þ (with large residual masses in the mediastinum or lung) were submitted to biopsy, which in
both cases revealed only fibrosis. In HD and aggressive NHL patients, PET positivity after induction treatment is highly predictive for
the presence of residual disease, with significant differences being observable in terms of RFS. PET negativity at restaging strongly
suggests the absence of active disease; histopathological verification is important in patients who show PET positivity.
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Both Hodgkin’s disease (HD) and aggressive non-Hodgkin’s
lymphoma (NHL) are curable malignancies. With standard
induction therapies (Armitage et al, 1986; DeVita et al, 1997;
Gianni et al, 1997) more than 70% of patients with HD and almost
half those with aggressive NHL can be cured. Many prognostic
indicators of response to treatment exist based on clinical
characteristics at presentation. The International Prognostic Index
(IPI) (The International non-Hodgkin’s Lymphoma Prognostic
Factors Project, 1993), which summarises different clinical
prognostic factors at diagnosis, has become an established
parameter for risk stratification in NHL. For HD, a specific
prognostic score has been devised for the identification different
risk subsets (Hasenclever and Diehl, 1998). After selecting correct,
specific frontline treatments on the basis of these prognostic scores
at the time of presentation, the next important steps are to: (i)
distinguish between responders to standard approaches and non-
responders who stand to benefit from an early change to an
alternative, experimental form of therapy; (ii) monitor and identify
any relapses during follow-up. Chemosensitivity and response to
treatment is currently assessed on the basis of clinical, radiological
and pathological (bone marrow) criteria.
X-ray computed tomography (CT) remains the gold standard for
evaluation of nodal disease. However, definition of response
criteria based on conventional radiographic characteristics re-
mains difficult, as lymphoma patients treated with chemotherapy
often present with residual masses of uncertain significance. These
residual masses may consist of fibrotic tissue or active disease and
CT scan and magnetic resonance imaging (MRI) cannot reliably
differentiate between active disease and fibrosis (Hill et al, 1993;
Zinzani et al, 1996). For these purposes, functional imaging with
fluorine-18 fluorodeoxyglucose (FDG) positron emission tomo-
graphy (PET) can reveal decisive metabolic or functional tissue
parameters and is more accurate than conventional radiological
imaging techniques for restaging after chemotherapy (Jerusalem
et al, 1999, 2001; Zinzani et al, 1999a,b; Kostakoglu and
Goldsmith, 2000; Dittmann et al, 2001). Several groups, including
our own, have evaluated the efficiency of PET for restaging
patients after completed therapy (Cremerius et al, 1998, 2001;
De Wit et al, 2001; Naumann et al, 2001; Spaepen et al,
2001a,b; Weihrauch et al, 2001, 2003; Zinzani et al, 2002; Fihnont
et al, 2003).
Herein, we report an extensive analysis of restaging after
induction treatment of patients with HD or aggressive NHL based
on PET in conjunction with CT and – in certain selected cases –
histopathological analysis.
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Patient population
All patients with HD or aggressive NHL who were treated at our
Institute with our standard induction chemotherapy protocols
(with/without radiation therapy) between October 2001 and
December 2002 were screened for this retrospective analysis.
Eligibility criteria were no prior therapy; histological diagnosis of
HD or aggressive NHL according to the R.E.A.L. classification
(Harris et al, 1994); an ECOG (Oken et al, 1982) performance
status score of o3; normal hepatic, renal, and cardiac function. All
patients provided informed consent for the study. Ethical approval
was not appropriate for this noninvasive study performed in
conjunction with routine chemotherapy protocols.
Induction treatment
Patients with HD were treated with four or six cycles of ABVD
regimen (Bonadonna et al, 1977), based on initial staging. Patients
with aggressive NHL were submitted to the MACOP-B regimen
(Klimo and Connors, 1985). Radiotherapy was performed at the
clinician’s discretion.
Staging
Radiological clinical staging with evaluation of tumour size
included CT and PET. CT was performed at diagnosis (before
therapy), 1 month after the end of chemotherapy, and 2 months
after any radiotherapy. PET was performed at least 1 month after
the end of chemotherapy, and 3 months after any radiotherapy.
The remaining staging procedures included bone marrow biopsy,
haematological and biochemical survey. A mass measuring
X10cm in its longest diameter was considered as bulky.
CT scans of the chest, abdomen, and pelvis were obtained using
a third generation General Electric scanner (GE Medical Systems,
Milwaukee, WI, USA). All the regions were scanned at 10 10mm
2
intervals; scan time was 2s. Intravenous contrast material (a bolus
of 100–150ml of nonionic contrast medium) was used in all
patients.
To optimise FDG uptake in normal and neoplastic tissue,
patients were asked to fast for at least 6h before undergoing PET
examination; no patient had a history of diabetes. Fluorine-18
fluorodeoxyglucose (FDG) was produced in our radiopharmacy
using standard synthesis techniques. Each patient was i.v. injected
with about 6MBqkg
 1 of FDG; PET scan was carried out 70–
90min after tracer injection. Before PET scanning patients were
encouraged to void in order to minimise activity in the bladder.
FDG-PET scans were carried out using a dedicated tomograph
(Advance NX, General Electric Medical Systems, Milwakee, USA).
Emission scans were acquired for 4min at every table positron; 2-
min transmission scans were also recorded in all patients. Overall,
about six bed positions were required for each patient, with a total
scan time of about 40min. Images were reconstructed with
segmented attenuation correction. PET images were evaluated on
the basis of image visual inspection by three experienced readers.
Areas of focal uptake were interpreted as positive for lymphoma
unless they were at the sites of known accumulation, including the
kidney and bladder, gastrointestinal tract, skeletal areas showing
symmetric joint uptake (especially within the shoulder) were
considered as due to arthritis.
Evaluation of response
Complete response (CR) was defined using reported standardised
guidelines (Cheson et al, 2000). For the purposes of this report,
results of PET were not considered when assigning response status
following therapy. The relapse-free survival (RFS) curve was
calculated using the Kaplan–Meier method (Kaplan and Meier,
1958). RFS was defined as the period from the end of therapy to the
time of first relapse. The statistical significance of differences
observed were assessed using the log-rank test (Mantel and
Haenzel, 1959).
RESULTS
In total, 75 patients satisfied the eligibility criteria (Table 1). After
completion of the respective chemotherapy programs (ABVD for
HD, MACOP-B for NHL), 45 out of 75 (60%) patients received
radiation therapy with a tumour dose of 30–36Gy.
Table 2 reports PET and CT restaging findings after induction
with respect to outcome. After the treatment, 59 out of 75 (79%)
patients were negative at PET, the remaining 16 being positive. In
total, 14 of the 16 (88%) patients who were PET
þ went on to have
local relapse/progression (at a median of 9 months after
completing induction therapy, range 3–12 months). By contrast,
none of the 59 patients who were PET
  had local relapse/
progression (P¼0.00001). Figure 1 shows the RFS curves for
patients who were PET
þ went after the induction treatment
(P¼0.00001).
Table 1 Patients’ characteristics
Number of patients (HD/aggressive NHL) 75 (41/34)
Age (years) Median 41
Range 16–60
Sex M 54 (72%)
F 21 (28%)
Symptoms No 40 (54%)
Yes 35 (46%)
Stage II 28 (37%)
III–IV 47 (63%)
Bulky disease 30 (40%)
Table 2 PET and CT scans: restaging results and clinical outcome
No. pts Relapses
CT
–/PET
– 29 0
CT
–/PET
+ 5 4 (80%)
CT
+/PET
+ 11 10 (91%)
CT
+/PET
– 30 0
100
%
80
60
40
20
0
0369 1 2 1 5
PET−
PET+
P=0.0000
Months
Figure 1 RFS curves of patients with PET negativity (n¼59) or PET
positivity (n¼16) after induction treatment.
PET in lymphoma patients
PL Zinzani et al
851
British Journal of Cancer (2004) 91(5), 850–854 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lAs regards CT, as many as 41 out of 75 (55%) patients had a
positive scan. Of these, 30 out of 41 (73%) were PET
 . All 30
(100%) patients in this PET
 /CT
þ subset are still in CR at a
median follow-up of 12 months (range, 6–15 months). Two of
these patients, both with HD, were submitted to histopathological
evaluation, due to evidence at CT of either diffuse mediastinal
residual disease or right lung infiltration. In both cases, the
histopathological findings (based on an intrathoracic biopsy and
lobectomy, respectively) were negative for lymphomatous infiltra-
tion, and revealed only fibrotic and necrotic tissue (Figure 2 shows
the negative PET scan of the patient who had suspected pulmonary
infiltration at CT). By contrast, in the PET
þ/CT
þ subset 10 out of
Figure 2 FDG PET (maximum intensity projection – MIP-image)
showing no area of increased uptake. PET transaxial image shows no left
lung increased uptake; corresponding transaxial CT image shows an
equivocal subpleural area of consolidation in the left lower lobe. After
lobectomy, this finding turned out to be benign (fibrosis and necrosis).
Figure 3 FDG PET (maximum intensity projection – MIP-image)
showing an area of increased uptake in a left latero-crevical lymph node
and a second area of increased uptake in abdomen, likely consistent with
juxtaintestinal lymph node. Corresponding transaxial PET and CT images
show the enlarged left laterocervical lymph node. Biopsy was positive for
lymphoma relapse.
PET in lymphoma patients
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l11 (91%) patients experienced local relapse/progression within the
first 12 months; in the remaining patient, a driven true-cut biopsy
guided by abdominal ultrasonography was performed at 3 months
(following a second positive PET scan), revealing a pathohistolo-
gical diagnosis of aggressive NHL.
Among the patients who were CT
 /PET
þ after treatment, only
one out of five (20%) is currently in CR; the remaining four (80%)
patients relapsed (after 3, 5, 9, and 12 months). All these five
patients were submitted to a lymph node biopsy: in the four
patients who relapsed histopathological confirmation was made of
either aggressive NHL (three cases) or HD ( one case); in the
remaining patient, the histopathological diagnosis was follicular
hyperplasia. By contrast, all 29 patients in the PET
 /CT
  subset
are now in CR with a median follow-up of 14 months.
It should be noted that biopsies performed in two patients who
were PET
  but strongly CT
þ revealed only fibrotic/necrotic tissue.
Figure 3 shows the positive PET scans of patient who had
histopathological confirmation of relapse.
DISCUSSION
This extended follow-up analysis strongly reinforces the positive
role of PET for optimal restaging of patients with HD or aggres-
sive NHL after induction chemotherapy with/without radiation
therapy.
Many lymphoma patients present with residual masses after
completing induction therapy, but less than 20% of them will
eventually relapse. Thus, detection of residual active lymphoma
after induction is of major clinical importance. Before the
introduction of PET for clinical evaluation of lymphoma patients,
no available tool could reliably predict the course of the disease.
None of the morphological characteristics described for CT scan
can differentiate active lymphoma from necrosis and fibrosis. MRI
has a low sensitivity and is therefore not useful for lymphoma (Hill
et al, 1993; Zinzani et al, 1996). Although 67-Gallium scintigraphy
is a metabolic imaging technique to detect active tumour tissue, it
has drawbacks such as a low spatial resolution and difficulty in
identifying residual abdominal masses (Kostakoglu et al, 1992;
Setoain et al, 1997; Zinzani et al, 1999a,b). In recent years, a series
of reports have shown that PET is the most helpful noninvasive
metabolic imaging technique for patients with either HD or
aggressive NHL: it can distinguish between active lymphoma and
fibrosis, and it has important prognostic value after completion of
front-line therapy (Cremerius et al, 1998, 2001; De Wit et al, 2001;
Naumann et al, 2001; Spaepen et al, 2001a,b; Weihrauch et al,
2001, 2003; Zinzani et al, 2002; Fihnont et al, 2003).
Our extensive analysis clearly indicates reliability of PET in the
post-treatment evaluation of HD and aggressive NHL with respect
to specific histopathological evaluation. There were no false-
negative results among the 75 PET scans performed and only one
false-positive result. Among the 16 patients who had positive PET
scans, 14 (88%) relapsed or progressed within 1 year from the end
of the treatment. Remarkably, surgical biopsy revealed persistence
of active disease in four out of the five (80%) patients in whom a
positivity at PET was accompanied by a negative CT scan. The
single false-positive PET finding corresponded to a histolopatho-
logical diagnosis of follicular hyperplasia. Biopsies were also
performed in two patients who were negative at PET due to the
large size of residual masses visualised at CT: in either case,
histopathological examination revealed only fibrotic/necrotic
tissue. The relevant impact of PET positivity on RFS, indepen-
dently of lymphoma type (HD or aggressive NHL) and presence/
absence of a positive CT scan can be clearly seen from Figure 1.
Taken together, these data suggest the need to reach a
histopathological diagnosis whenever possible before commencing
salvage therapy, rather than relying exclusively on a positive PET
result. On the other hand, the apparently strong negative
predictive value of PET suggests that biopsy might be reserved
for cases of PET positivity.
An interesting development in the role of PET for HD and
aggressive NHL patients will be to verify and to confirm the
preliminary data reported by Spaepen et al (2002) concerning the
possible role of an early PET scan performed after a few courses of
induction chemotherapy for identification and stratification of
responder and nonresponder patients. This could lead to inclusion
of PET in a specific mixed prognostic score including biological,
clinical and imaging parameters. In addition, recent reports
indicate that PET can be used to predict the clinical outcome
after high-dose chemotherapy and stem cell transplantation
(Becherer et al, 2002; Cremerius et al, 2002; Spaepen et al, 2003).
In both situations, histopathological diagnosis will remain
important for deciding further treatment of patients with positive
PET scans.
A further step will be evaluation of the utility of combined PET/
CT (Visvikis and Ell, 2003). In the last few months, we have
initiated a prospective study to assess the possible predictive role
of PET/CT during induction chemotherapy (after one-third and
two-thirds of the courses) for patients with HD and aggressive
NHL in our institutions.
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